Mr Göktuğ Aba
Research:
Göktuğ Aba is working as a PhD student at the LUMC and he is combining the DNA nanotechnology with immunology to develop new agonistic antibody-based immunotherapeutics. His interests lie in the activation of co-stimulatory T-cell receptors with agonistic nanobodies to bypass T-cell exhaustion and induce activation.
Curriculum Vitae:
Göktuğ studied Life Science and Technology at TU Delft and Leiden University. He obtained his masters in Life Science and Technology at Leiden University where he did his internship in the group of Sander van Kasteren. Göktuğ combined the cytotoxic activity of cytokines with targeting properties of nanobodies to develop a new immunocytokine with reduced side effects, potentially to be used as anti-cancer drug. He started his PhD in 2021 in the CCB group at the LUMC supervised by Thom Sharp and Ferenc Scheeren.
